Share on StockTwits

Acceleron Pharma (NASDAQ:XLRN) CFO Kevin F. Mclaughlin sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $29.78, for a total transaction of $297,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on XLRN. Analysts at Leerink Swann initiated coverage on shares of Acceleron Pharma in a research note on Thursday. They set an “outperform” rating and a $57.00 price target on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Acceleron Pharma in a research note on Wednesday. They set an “outperform” rating and a $47.00 price target on the stock. Four research analysts have rated the stock with a buy rating, Acceleron Pharma presently has an average rating of “Buy” and an average target price of $51.00.

Acceleron Pharma (NASDAQ:XLRN) traded down 0.50% during mid-day trading on Friday, hitting $29.81. 140,234 shares of the company’s stock traded hands. Acceleron Pharma has a one year low of $16.78 and a one year high of $57.89. The stock has a 50-day moving average of $29.77 and a 200-day moving average of $36.09. The company’s market cap is $947.9 million.

Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.54) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.55) by $0.01. On average, analysts predict that Acceleron Pharma will post $-1.44 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.